The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects.
Open accessAbstract
The three major isoforms of human apolipoprotein E (apo-E2, -E3, and -E4) are coded for by three alleles (epsilon 2, epsilon 3, and epsilon 4) which have a common genetic locus. Previously, we demonstrated that E2, E3, and E4 differ in primary structure from one another at two substitution sites, site A (residue 112) and site B (residue 158). At sites A/B, apo-E2, -E3, and -E4 contain cysteine/cysteine, cysteine/arginine, and arginine/arginine, respectively. We demonstrated that the substitution of cysteine for arginine at site B is at least partly responsible for the defective binding of apo-E2 to human fibroblast low density lipoprotein receptors, compared to the normal binding activity of apo-E3 or -E4. Subjects with the genetic disorder type III hyperlipoproteinemia are phenotypically homozygous for apo-E2, but the binding activity of apo-E to the fibroblast receptor differs considerably from one type III individual to another. We therefore undertook a partial comparative sequence analysis of apo-E2 from three type III subjects whose apo-E displayed this heterogeneity. The subject with the poorest binding apo-E2 was genotypically homozygous for an apo-E allele (epsilon 2); cysteine was found at sites A and B. The subject with the most active apo-E2 was genotypically homozygous for an apo-E allele (epsilon 2); cystine was found at site A and at a new site (site C, residue 145). The epsilon 2 allele specifies a protein that has arginine at site B (residue 158); the epsilon 2 allele specifies a protein that has arginine at site C (residue 145). Therefore, the two alleles differ from one another by cysteine/arginine interchanges at two positions, sites B and C. The third subject, whose apo-E2 displayed binding activity intermediate between the activities of the other two, was genotypically heterozygous, having one epsilon 2 allele and one epsilon 2 allele. The intermediate binding activity of apo-E2 from this subject resulted from having a mixture of severely defective apo-E (specified by epsilon 2) and slightly defective apo-E (specified by epsilon 2).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Three variants ofapo E2 have been described.Each ofthese differs from apo E3 by a single amino acid substitution (6, 12- 14).”
From Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. (1987) · cites this paper as [14]
In the citing paper
“The most common has a mutation of 158 Arg --Cys (13), but mutations of 145 Arg -* Cys (14) and 146 Lys --Gln (6) have also been reported in individuals with type III hyperlipoproteinemia.”
From Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. (1987) · cites this paper as [14]
In the citing paper
“Homozygosity and heterozygocity for the apoE variant apoE3[R145C] has also been associated with severe type III HLP [30], [31].”
From Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia (2011) · cites this paper as [30]
In the citing paper
“and the 22-kDa domain of lipid-bound apoE3[R145C] has 48% reduced HSPG binding capacity compared to apoE3-22kDa [30], [32].”
From Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia (2011) · cites this paper as [30]
In the citing paper
“Binding studies showed that lipid-bound apoE3[R145C] has 55% reduced LDL receptor binding capacity compared to apoE3”
From Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia (2011) · cites this paper as [30]
In the citing paper
“Still, these variants not only maintain their ability to predispose to type III HLP, but also do so in a dominant fashion, unlike apoE2 [22], [26], [30], [31], [33], [34], [35].”
From Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia (2011) · cites this paper as [30]
In the citing paper
“In contrast, all apoE3 variants studied here demonstrate stronger LDL receptor binding compared to wild-type apoE2 [28], [30], [34], [35].”
From Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia (2011) · cites this paper as [30]
In the citing paper
“While heterozygosity for three further mutants (apoE2(145 Arg→Cys) (32, 33), apoE2(146 Lys→Gln) (34), or apoE2-Christchurch(136 Arg→Ser) (18, 33)) is associated with type III hyperlipoproteinemia, there are no family studies to ascertain whether these variants also demonstrate a dominant mode of inheritance.”
From Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121–127 (1989) · cites this paper as [32]
In the citing paper
“Prior studies [7][8][9] and Alzheimer Disease Sequencing Project (ADSP) data have shown that R145C is always in phase with ε3 and R150H is always in phase with ε2.”
From Association of African Ancestry–Specific APOE Missense Variant R145C With Risk of Alzheimer Disease (2023) · cites this paper as [8]
Citations
Cites
Weisgraber, K. H., Rall, S. C., & Mahley, R. W. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52510-8 · Cited by 777
Self-citationHuman apolipoprotein E. The complete amino acid sequence
Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34702-1 · Cited by 741
Self-citationWeisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34954-8 · Cited by 673
Self-citationZannis, V. I., & Breslow, J. L. (1981) · Biochemistry · doi:10.1021/bi00507a059 · Cited by 563
Innerarity, T. L., & Mahley, R. W. (1978) · Biochemistry · doi:10.1021/bi00601a013 · Cited by 433
Self-citationSherrill, B. C., Innerarity, T. L., & Mahley, R. W. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85951-3 · Cited by 426
Self-citationPolymorphism of apolipoprotein E
Utermann, G., Vogelberg, K. H., Steinmetz, A., Schoenborn, W., Pruin, N., Jaeschke, M., Hees, M. T. I. W. S.-V., & Canzler, H. (1979) · Clinical Genetics · doi:10.1111/j.1399-0004.1979.tb02027.x · Cited by 408
Lipoprotein binding to canine hepatic membranes. Metabolically distinct apo-E and apo-B,E receptors.
Hui, D. Y., Innerarity, T. L., & Mahley, R. W. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69254-9 · Cited by 383
Self-citationMahley, R. W., Hui, D. Y., Innerarity, T. L., & Weisgraber, K. H. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110365 · Cited by 373
Self-citation(1981) · PubMed · Cited by 341
Cited by
Sorted by citations
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Self-citationApolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981
Plasma lipoproteins: apolipoprotein structure and function.
Mahley, R. W., Innerarity, T. L., Rall, S. C., & Weisgraber, K. H. (1984) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34443-6 · Cited by 1,155
Self-citationApolipoprotein E: Structure-Function Relationships
Weisgraber, K. H. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60642-7 · Cited by 830
Self-citation(1985) · PubMed · Cited by 706
Familial lipoprotein disorders in patients with premature coronary artery disease.
Genest, J. J., Martin-Munley, S., McNamara, J. R., Ordovás, J. M., Jenner, J. L., Myers, R. H., Silberman, S. R., Wilson, P. W., Salem, D. N., & Schaefer, E. J. (1992) · Circulation · doi:10.1161/01.cir.85.6.2025 · Cited by 598
Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic.
Brown, M. S., & Goldstein, J. L. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111044 · Cited by 545
Elshourbagy, N. A., Liao, W. S., Mahley, R. W., & Taylor, J. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.1.203 · Cited by 376
Self-citationMahley, R. W., Huang, Y., & Rall, S. C. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32417-2 · Cited by 447
Self-citationEhnholm, C., Lukka, M., Kuusi, T., Nikkilä, E. A., & Utermann, G. (1987) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38833-7 · Cited by 403
Apolipoprotein E polymorphism in health and disease
Utermann, G. (1987) · American Heart Journal · doi:10.1016/0002-8703(87)90610-7 · Cited by 389
Isolation, characterization, and mapping to chromosome 19 of the human apolipoprotein E gene.
Das, H. K., McPherson, J. D., Bruns, G. A. P., Karathanasis, S. K., & Breslow, J. L. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)88963-3 · Cited by 354
The impact of low-frequency and rare variants on lipid levels
ENGAGE Consortium, Surakka, I., Horikoshi, M., Mägi, R., Sarin, A.-P., Mahajan, A., Lagou, V., Marullo, L., Ferreira, T., Miraglio, B., et al. (2015) · Nature Genetics · doi:10.1038/ng.3300 · Cited by 351
Apolipoprotein E polymorphism and coronary artery disease.
Menzel, H. J., Kladetzky, R. G., & Assmann, G. (1983) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.3.4.310 · Cited by 344
Li, W., Tanimura, M., Luo, C. C., Datta, S., & Chan, L. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38532-1 · Cited by 316
Windler, E. E. T., & Havel, R. J. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34342-x · Cited by 314
Familial apolipoprotein E deficiency.
Schaefer, E. J., Gregg, R. E., Ghiselli, G., Forte, T. M., Ordovas, J. M., Zech, L. A., & Brewer, H. B. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112704 · Cited by 313
Genotyping and sequence analysis of apolipoprotein E isoforms*1
EMI, M. (1988) · Genomics · doi:10.1016/0888-7543(88)90130-9 · Cited by 301
Nucleotide sequence and structure of the human apolipoprotein E gene.
Paik, Y. K., Chang, D. J., Reardon, C. A., Davies, G. E., Mahley, R. W., & Taylor, J. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.10.3445 · Cited by 281
Self-citationThe receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments.
Innerarity, T. L., Friedlander, E. J., Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44180-9 · Cited by 276
Self-citationThe involvement of Reelin in neurodevelopmental disorders
Folsom, T. D., & Fatemi, S. H. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.08.015 · Cited by 275
A rapid micromethod for apolipoprotein E phenotyping directly in serum
Havekes, L. M., de Knijff, P., Beisiegel†, U., HAVINGA, J. R., de Smit, M. H., & Klasen, E. C. (1987) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38697-1 · Cited by 262
Huang, Y., Weisgraber, K. H., Mucke, L., & Mahley, R. W. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:189 · Cited by 242
Self-citationHuman apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3.
Weisgraber, K. H., Rall, S. C., Mahley, R. W., Milne, R. W., Marcel, Y. L., & Sparrow, J. T. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35898-2 · Cited by 240
Self-citationApolipoprotein E phenotypes and hyperlipidemia
Utermann, G., Kindermann, I., Kaffarnik, H., & Steinmetz, A. (1984) · Human Genetics · doi:10.1007/bf00286508 · Cited by 238
Ordovas, J. M., Litwack-Klein, L., Wilson, P. W., Schaefer, M. M., & Schaefer, E. J. (1987) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38690-9 · Cited by 238
Striekland, D. K., Ashcom, J. D., Williams, S. E., Battey, F. D., Behre, E., Mctigue, K., Battey, J. F., & Argraves, W. S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98848-4 · Cited by 229
Laws, S. M., Hone, E., Gandy, S., & Martins, R. N. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01615.x · Cited by 223
Genetic factors affecting blood lipoproteins: the candidate gene approach.
Lusis, A. J. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38516-3 · Cited by 219
Pathogenesis and Management of Lipoprotein Disorders
Flier, J. S., Underhill, L. H., Schaefer, E. J., & Levy, R. I. (1985) · New England Journal of Medicine · doi:10.1056/nejm198505163122007 · Cited by 213
Ordovás, J. M., Schaefer, E. J., Salem, D. N., Ward, R. H., Glueck, C. J., Vergani, C., Wilson, P. W. F., & Karathanasis, S. K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603133141102 · Cited by 203
Apolipoproteins in the brain: implications for neurological and psychiatric disorders
Elliott, D. A., Weickert, C. S., & Garner, B. (2010) · Clinical Lipidology · doi:10.2217/clp.10.37 · Cited by 194
Synthesis, intracellular processing, and signal peptide of human apolipoprotein E.
Zannis, V. I., McPherson, J. D., Goldberger, G., Karathanasis, S. K., & Breslow, J. L. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)91039-2 · Cited by 189
The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease
Beffert, U. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00008-3 · Cited by 190
Pathogenesis and Management of Lipoprotein Disorders
Fredman, S. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603273141310 · Cited by 187
Ruiz, J., Kouiavskaia, D., Migliorini, M., Robinson, S., Saenko, E. L., Gorlatova, N., Li, D., Lawrence, D., Hyman, B. T., Weisgraber, K. H., et al. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500114-jlr200 · Cited by 204
Self-citationInnerarity, T. L., Weisgraber, K. H., Arnold, K. S., Rall, S. C., & Mahley, R. W. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39866-6 · Cited by 179
Self-citationApolipoprotein E phenotyping from serum by Western blotting
Menzel, H., & Utermann, G. (1986) · Electrophoresis · doi:10.1002/elps.1150071103 · Cited by 174
Role of apolipoprotein E in neurodegenerative diseases
Giau, V. V., Bagyinszky, E., An, S. S. A., & Kim, S. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84266 · Cited by 177
Koch, W., Ehrenhaft, A., Grießer, K., Pfeufer, A., Mueller, J. C., Schömig, A., & Kastrati, A. (2002) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2002.197 · Cited by 169
APOE gene variants in primary dyslipidemia
Khalil, Y. A., Rabès, J.-P., Boileau, C., & Varret, M. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.007 · Cited by 170
The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding.
Weisgraber, K. H., Innerarity, T. L., Harder, K. J., Mahley, R. W., Milne, R. W., Marcel, Y. L., & Sparrow, J. T. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44181-0 · Cited by 220
Self-citationGianturco, S. H., Gotto, A. M., Hwang, S. L., Karlin, J. B., Lin, A., Prasad, S. C., & Bradley, W. A. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32655-3 · Cited by 161
Wardell, M. R., Brennan, S. O., Janus, E. D., Fraser, R., & Carrell, R. W. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113096 · Cited by 159
Human apolipoprotein E mRNA. cDNA cloning and nucleotide sequencing of a new variant.
McLean, J. W., Elshourbagy, N. A., Chang, D. J., Mahley, R. W., & Taylor, J. M. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82169-3 · Cited by 150
Self-citationThe role of apolipoprotein E genetic variants in lipoprotein disorders.
RALL, S. C., & MAHLEY, R. W. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb01254.x · Cited by 150
Self-citationApolipoprotein E phenotypes in patients with myocardial infarction
Utermann, G., Hardewig, A., & Zimmer, F. (1984) · Human Genetics · doi:10.1007/bf00286509 · Cited by 150
Beyond the CNS: The many peripheral roles of APOE
Martínez-Martínez, A. B., Torres-Perez, E., Devanney, N., Del Moral, R., Johnson, L. A., & Arbones-Mainar, J. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104809 · Cited by 149
Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels
de Knijff, P., van den Maagdenberg, A. M. J. M., Frants, R. R., & Havekes, L. M. (1994) · Human Mutation · doi:10.1002/humu.1380040303 · Cited by 137
Ehnholm, C., Mahley, R. W., Chappell, D. A., Weisgraber, K. H., Ludwig, E. H., & Witztum, J. L. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.17.5566 · Cited by 137
Self-citationRat apolipoprotein E mRNA. Cloning and sequencing of double-stranded cDNA.
McLean, J. W., Fukazawa, C., & Taylor, J. M. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32155-0 · Cited by 136
Hui, D. Y., Innerarity, T. L., & Mahley, R. W. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)43536-8 · Cited by 128
Self-citationSmit, M., de Knijff, P., Rosseneu, M., Bury, J., Klasen, E., Frants, R., & Havekes, L. (1988) · Human Genetics · doi:10.1007/bf01790099 · Cited by 127
Rasmussen, K. L. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.037 · Cited by 125
Kinetics of chylomicron remnant clearance in normal and in hyperlipoproteinemic subjects.
Cortner, J. A., Coates, P. M., Le, N., Cryer, D. R., Ragni, M. C., Faulkner, A., & Langer, T. (1987) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38721-6 · Cited by 123
Dermal, subcutaneous, and tendon xanthomas: Diagnostic markers for specific lipoprotein disorders
Cruz, P. D., East, C. A., & Bergstresser, P. R. (1988) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(88)70157-7 · Cited by 121
Angelin, B., Raviola, C. A., Innerarity, T. L., & Mahley, R. W. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110835 · Cited by 120
Self-citationThe 39-kDa Receptor-associated Protein Modulates Lipoprotein Catabolism by Binding to LDL Receptors
Medh, J. D., Fry, G. L., Bowen, S. L., Pladet, M. W., Strickland, D. K., & Chappell, D. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.536 · Cited by 94
Smith, J. D., Melián, A., Leff, T., & Breslow, J. L. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68477-7 · Cited by 114
Behavior of human apolipoprotein E in aqueous solutions and at interfaces.
Yokoyama, S., Kawai, Y., Tajima, S., & Yamamoto, A. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36247-6 · Cited by 114
Wu, Y., Waite, L. L., Jackson, A., Sheu, W. H., Buyske, S. G., Absher, D., Arnett, D. K., Boerwinkle, E., Bonnycastle, L. L., Carty, C. L., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003379 · Cited by 112
The Genetics of Alzheimer’s Disease
Barber, R. C. (2012) · Scientifica · doi:10.6064/2012/246210 · Cited by 122
Weisgraber, K. H., Rall, S. C., Innerarity, T. L., Mahley, R. W., Kuusi, T., & Ehnholm, C. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111287 · Cited by 111
Self-citationHuman apolipoprotein A-I--C-III gene complex is located on chromosome 11.
Bruns, G. A. P., Karathanasis, S. K., & Breslow, J. L. (1984) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.4.2.97 · Cited by 110
Potential biomarkers in psychiatry: focus on the cholesterol system
Woods, A. G., Sokolowska, I., Taurines, R., Gerlach, M., Dudley, E., Thome, J., & Darie, C. C. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01543.x · Cited by 106
Rall, S. C., Weisgraber, K. H., Innerarity, T. L., Bersot, T. P., Mahley, R. W., & Blum, C. B. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111085 · Cited by 141
Self-citationApolipoprotein E synthesis in peripheral tissues of nonhuman primates.
Williams, D. L., Dawson, P. A., Newman, T. C., & Rudel, L. L. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89574-6 · Cited by 105
de Knijff, P., van den Maagdenberg, A. M., Stalenhoef, A. F., Leuven, J. A., Demacker, P. N., Kuyt, L. P., Frants, R. R., & Havekes, L. M. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115349 · Cited by 100
Identification and DNA sequence of a human apolipoprotein E cDNA clone.
Breslow, J. L., McPherson, J. D., NUSSBAUM, A. L., Williams, H. W., Lofquist-Kahl, F., Karathanasis, S. K., & Zannis, V. I. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)33328-3 · Cited by 99
Havekes, L., de Wit, E., Leuven, J. G., Klasen, E., Utermann, W., Weber, W., & Beisiegel, U. (1986) · Human Genetics · doi:10.1007/bf00291607 · Cited by 99
Functional Characterization of Apolipoprotein E Isoforms Overexpressed in Escherichia coli
Morrow, J. A., Arnold, K. S., & Weisgraber, K. H. (1999) · Protein Expression and Purification · doi:10.1006/prep.1999.1069 · Cited by 94
Self-citationCladaras, C., Hadzopoulou-Cladaras, M., Felber, B. K., Pavlakis, G., & Zannis, V. I. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)61655-2 · Cited by 92
Evolution of apolipoprotein E: mouse sequence and evidence for an 11-nucleotide ancestral unit
Rajavashisth, T. B., Kaptein, J. S., Reue, K. L., & Lusis, A. J. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.23.8085 · Cited by 65
Yamamura, T., Yamamoto, A., Sumiyoshi, T., Hiramori, K., Nishioeda, Y., & Nambu, S. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111532 · Cited by 91
Rall, S. C., Weisgraber, K. H., Innerarity, T. L., Mahley, R. W., & Assmann, G. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110829 · Cited by 90
Self-citationApolipoprotein E metabolism in normolipoproteinemic human subjects.
Gregg, R., Zech, L., Schaefer, E., & Brewer, H. (1984) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34460-6 · Cited by 90
Bolla, M. K., Haddad, L., Humphries, S. E., WINDER, A. F., & Day, I. N. M. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.11.1599 · Cited by 90
Genetic basis of lipoprotein disorders.
Breslow, J. L. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114176 · Cited by 91
Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3.
Havel, R. J., Kotite, L., Kane, J. P., Tun, P., & Bersot, T. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110978 · Cited by 88
Vogel, T., Weisgraber, K. H., Zeevi, M. I., Ben-Artzi, H., Levanon, A. Z., Rall, S. C., Innerarity, T. L., Hui, D. Y., Taylor, J. M., & Kanner, D. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.24.8696 · Cited by 88
Self-citationSniderman, A. D., Tremblay, A., Bergeron, J., Gagné, C., & Couture, P. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.07.006 · Cited by 87
Thakkinstian, A., Bowe, S. J., McEvoy, M., Smith, W. T., & Attia, J. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj279 · Cited by 87
Nucleotide sequence of cloned cDNA of human apolipoprotein A-l
Cheung, P., & Chan, L. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.11.3703 · Cited by 87
Rall, S. C., Newhouse, Y. M., Clarke, H. R., Weisgraber, K. H., McCarthy, B. J., Mahley, R. W., & Bersot, T. P. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113988 · Cited by 103
Self-citationMechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.
Huang, Y. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833af368 · Cited by 82
Wardell, M. R., Weisgraber, K. H., Havekes, L. M., & Rall, S. C. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)30067-5 · Cited by 80
Self-citationGenetic Mutations Affecting Human Lipoproteins, Their Receptors, and Their Enzymes
Zannis, V. I., Kardassis, D., & Zanni, E. E. (1993) · Advances in Human Genetics 21 · doi:10.1007/978-1-4615-3010-7_3 · Cited by 78
MAHLEY, R. W., INNERARITY, T. L., RALL, S. C., & WEISGRABER, K. H. (1985) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1985.tb11860.x · Cited by 75
Self-citationSmit, M., de Knijff, P., van der Kooij-Meijs, E., Groenendijk, C., van den Maagdenberg, A., Gevers Leuven, J., Stalenhoef, A., Stuyt, P., Frants, R., & Havekes, L. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42759-2 · Cited by 74
Scott, J., Knott, T. J., Shaw, D. J., & Brook, J. D. (1985) · Human Genetics · doi:10.1007/bf00283370 · Cited by 73
Genetic Defects in Lipoprotein Metabolism
Mahley, R. W. (1991) · JAMA · doi:10.1001/jama.265.1.78 · Cited by 84
Self-citationA new isoform of apolipoprotein E — Apo E-5 — Associated with hyperlipidemia and atherosclerosis
Yamamura, T., Yamamoto, A., Hiramori, K., & Nambu, S. (1984) · Atherosclerosis · doi:10.1016/0021-9150(84)90019-4 · Cited by 70
Stalenhoef, A. F., Malloy, M. J., Kane, J. P., & Havel, R. J. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112632 · Cited by 70
Pedersen, J. C., & Berg, K. (1989) · Clinical Genetics · doi:10.1111/j.1399-0004.1989.tb02953.x · Cited by 70
Receptor-mediated mechanisms of lipoprotein remnant catabolism
Chappell, D. A., & Medh, J. D. (1998) · Progress in Lipid Research · doi:10.1016/s0163-7827(98)00017-4 · Cited by 70
Lin-Lee, Y.-C., Kao, F. T., Cheung, P., & Chan, L. (1985) · Biochemistry · doi:10.1021/bi00335a050 · Cited by 68
Menzel, H. J., Assmann, G., Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)43261-3 · Cited by 67
Self-citationMilne, R. W., WEECH, P. K., Blanchette, L., Davignon, J., Alaupovic, P., & Marcel, Y. L. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111276 · Cited by 67
Apolipoprotein E and central nervous system disorders: Reviews of clinical findings
Takeda, M., Martínez, R., Kudo, T., Tanaka, T., Okochi, M., Tagami, S., Morihara, T., Hashimoto, R., & Cacabelos, R. (2010) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2010.02148.x · Cited by 66
Sepehrnia, B., Kamboh, M. I., Adams-Campbell, L. L., Bunker, C. H., Nwankwo, M. U., Majumder, P. P., & Ferrell, R. E. (1989) · PubMed · Cited by 65
Metadata
- Authors
- Rall, S. C., Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W.
- ORCID
- Mahley, R W
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 1982-08
- Volume
- 79
- Issue
- 15
- Pages
- 4696-4700
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC346743
- OpenAlex
- W2081151510
- Cited by
- 345
- References
- 16
- Citations by year
- 2024: 7 · 2023: 2 · 2022: 5 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 6 · 2014: 4 · 2013: 3 · 2012: 7
- FWCI
- 54.05
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- apolipoprotein E, type III hyperlipoproteinemia, LDL receptor, apolipoprotein E isoforms, site-directed mutagenesis, receptor binding activity, genetic polymorphism
- MeSH terms
- Alleles, Amino Acid Sequence, Apolipoproteins, Apolipoproteins E, Genes, Humans, Hyperlipoproteinemia Type III, Receptors, Cell Surface, Low Density Lipoprotein Receptor-Related Protein-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review